Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Estimating treatment effect in randomized trial after control to treatment crossover using external controls

Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting

A Causal Inference Framework for Leveraging External Controls in Hybrid Trials

Robust integration of external control data in randomized trials

Adaptive Hybrid Control Design for Comparative Clinical Trials with Historical Control Data

Estimation of Causal Effect in Integrating Randomized Clinical Trial and Observational Data – an Example Application to Cardiovascular Outcome Trial

Improving efficiency of inference in clinical trials with external control data

A matching design for augmenting a randomized clinical trial with external control

Integrating Randomized Placebo-Controlled Trial Data with External Controls: A Semiparametric Approach with Selective Borrowing

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Matching within a hybrid RCT/RWD: framework on associated causal estimands

A meta-analytic framework to adjust for bias in external control studies

Identification and estimation of treatment effects on long-term outcomes in clinical trials with external observational data

Statistical methods to control for confounders in rare disease settings that use external control

A Practical Analysis Procedure on Generalizing Comparative Effectiveness in the Randomized Clinical Trial to the Real-world Trialeligible Population

An Instrumental Variable Approach to Learning the Causal Exposure-Response Relationship in a Randomized Dose Comparison Trial

Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation

Enhancing Statistical Validity and Power in Hybrid Controlled Trials: A Randomization Inference Approach with Conformal Selective Borrowing

Leveraging real-world data to conduct externally controlled trial for rare diseases with count-type endpoints: utilizing multiple entries – a simulation study

Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials with Time-to-Event Outcomes under ICH E9 (R1)

Evaluating causal effects on time-to-event outcomes in an RCT in Oncology with treatment discontinuation due to adverse events